Strategies for an HIV vaccine

Journal of Clinical Investigation

Volumn 110, Issue 1, 2002, Pages 15-20

  Letvin, Norman L ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; LIVE VACCINE; RECOMBINANT PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG DESIGN; IMMUNOPATHOGENESIS; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS PARTICLE;

AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS;

EID: 0036308097     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200215985     Document Type: Review

References (27)

1. HIV-1 sequence variation: Drift, shift, and attenuation
2. Pathogenic diversity of simian immunodeficiency viruses
3. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
4. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
5. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication
6. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
7. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
8. Phenotypic analysis of antigen-specific T lymphocytes
9. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
10. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
11. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
12. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
13. A formalin-inactivated whole SIV vaccine confers protection in macaques
14. Anti-cell antibody in macaques
15. Initial studies on active immunization of HIV infected subjects using a gp120-depleted HIV-1 immunogen: Long-term follow-up
16. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
17. Simian immunodeficiency virus (SIV)gag DNAvaccinated rhesus monkeys develop secondary cycotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
18. Control of a mucosal challenge and prevention of clinical AIDS in rhesus monkeys by a multiprotein DNA/MVA vaccine
19. Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes
20. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
21. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
22. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
23. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
24. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
25. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
26. Viral load and heterosexual transmission of human immunodeficiency virus type 1
27. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes